· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2015 / N 3 Иммунные факторы риска прогрессирования облитерирующего атеросклероза артерий нижних конечностей: современное состояние вопроса (библиография) Б.В. Болдин, С.В. Родионов, П.Ю. Туркин, П.Ю. Голосницкий, Г.А. Варич, О.П. Лисенков, К.В. Комов, Г.Т. Мнацаканян, А.С. Фукалов, М.В. Добрянский, А.Ю. Заров 1. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011. 2. Покровский А.В. Клиническая ангиология: руководство для врачей. М.: Медицина, 2004. 3. Donker J.M., Ho G.H., Te Slaa A. et al. Midterm results of autologous saphenous vein and ePTFE pre-cuffed bypass surgery in peripheral arterial occlusive disease // Vasc. Endovascular. Surg. 2011. V. 7. № 45. P. 598–603. 4. Venermo M., Björck M. Critical limb ischaemia--from art to evidence // Scand. J. Surg. 2012. V. 2. № 101. P. 74–77. 5. Kechagias A., Ylönen K., Kechagias G. et al. Limits of infrainguinal bypass surgery for critical leg ischemia in high-risk patients (Finnvasc score 3–4) // Ann. Vasc. Surg. 2012. V. 2. № 26. P. 213–218. 6. Васюк Ю.А., Дударенко О.П., Ющук Е.Н. и др. Цитокиновая модель патогенеза хронической сердечной недостаточности и возможности нового терапевтического подхода в лечении декомпенсированных больных // Рацион. фармакотер. в кардиол. 2006. № 4. С. 63–70. 7. Калюжин В.В. Патогенез хронической сердечной недостаточности: изменение доминирующей парадигмы // Бюл. сиб. мед. 2007. № 4. С. 71–79. 8. Hedayat M., Mahmoudi M.J., Rose N.R., Rezaei N. Proinflammatory cytokines in heart failure: double–edged swords // Heart Fail. Rev. 2010. V. 15. № 6. P. 543–562. 9. Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных исследований. М.: Медицина, 2006. 10. Tanindi A., Sahinarslan A., Elbeg S., Cemri M. Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease // Open. Cardiovasc. Med. J. 2011. V. 5. P. 110–116. 11. Dynnik O.B., Gavrilenko T.I., Zalesskiĭ V.N. Apoptosis of cardiomyocytes, cytokines and remodeling of myocardium against the development of chronic heart failure // Lik. Sprava. 2005. V. 5/6. P. 3–10. 12. Hedman A., Larsson P. T., Alam M. et al. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? // Int. J. Cardiol. 2007. V. 120. № 1. P. 108–114. 13. Антонова А.В., Шевченко А.О., Кочетова Е.В. Атеросклероз, ишемическая болезнь сердца, острый коронарный синдром // Вестн. РГМУ. 2005. Т. 42. С. 3–5. 14. Кухарчук В.В., Зыков К.А., Масенко В.П. и др. Динамика воспалительного процесса у больных с острым коронарным синдромом и больных со стабильной стенокардией. Сообщение. Биохимические и иммунологические аспекты // Кардиол. вестн. 2007. Т. 2. № 2. С. 3–13. 15. Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных исследований. М.: Медицина, 2006. 16. Skoog T., Dichtl W., Boquist S. et al. Plasma tumor necrosis factor and early carotid atherosclerosis in healthy middle-age men // Eur. Heart J. 2002. V. 23. P. 376–383. 17. Zimmerman M., Selzman C., Reznikov L.L. et al. Lack of TNF-α attenuates intimal hyperplasia after mouse carotid artery injury// Am. J. Physiol. Reg. Integrat. Comp. Physiol. 2002. . V. 283. P. 505–512. 18. Blann A.D., McCollum C.N. Increased levels of tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels tumor necrosis factor // Inflammation. 1998. V. 22. P. 483–491. 19. Elkind M.S., Cheng J., Boden-Albata B. et al. Tumor necrosis factor levels are associated with carotid atherosclerosis // Stroke. 2002. V. 33. P. 31–38. 20. Ridker P.M., Rifai N., Pfefer M. et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction // Circulation. 2000. V. 101. P. 2149–2153. 21. Price D.T., Loscalzo J. Cellular adhesion molecules and atherogenesis // The Am. J. Med. 1999. V. 107. № 1. P. 85–97. 22. Galkina E., Ley K. Vascular adhesion molecules in atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. V. 27. № 11. P. 2292–2301. 23. Pradhan A.D., Rifai N., Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men // Circulation. 2002. V. 106. № 7. P. 820–825. 24. Hubbard A.K., Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades // Free Radic. Biol. Med. 2000. V. 28. P. 1379–1386. 25. Postigo A.A., Teixido J., Sanchez-Madrid F. The alpha 4 beta 1/VCAM-1 adhesion pathway in physiology and disease // Res. Immunol. 1993. V. 144. P. 723–735. Disc. 754–762. 26. Carter R.A., Wicks I.P. Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of joint inflammation // Arthritis Rheum. 2001. V. 44. P. 985–994. 27. Leca G., Mansur S.E., Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones. Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform // J. Immunol. 1995. V. 154. P. 1069–1077. 28. Libby P. Changing concepts of atherogenesis // J. Int. Med. 2000. V. 247. № 3. P. 349–358. 29. Huo Y., Ley K. Adhesion molecules and atherogenesis // Acta Physiology. 2001. V. 173. № 1. P. 35–43. 30. Galkina E., Ley K. Vascular adhesion molecules in atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. V. 27. № 11. P. 2292–2301. 31. Pradhan A.D., Rifai N., Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men // Circulation. 2002. V. 106. № 7. P. 820–825. 32. Silvestro A., Brevetti G., Schiano V. et al. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification // Thromb. Нaemost. 2005. V. 93. № 3. P. 559–563. 33. Yang M., Fu Z., Zhang Q. et al. Association between the polymorphisms in intercellular adhesion molecule-1 and the risk of coronary atherosclerosis: a case-controlled study // PLoS One. 2014. V. 9. № 10. P. e109658. 34. Gross M.D., Bielinski S.J., Suarez-Lopez J.R. et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study // Clin. Chem. 2012. V. 58. № 2. P. 411–420. 35. de Lemos J.A., Hennekens C.H, Ridker P.M. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk // 2000. V. 36. № 2. P. 423–426. 36. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease // Nat. Clin. Pract. Cardiovasc. Med. 2006. V. 3. № 1. P. 35–42. 37. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: exploring the connection // Arterioscler. Thromb. Vasc. Biol. 2007. V. 27. № 5. P. 996–1003. 38. Yousuf O., Mohanty B.D., Martin S.S. et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? // 2013. V. 62. № 5. P. 397–408. 39. Silva D., Pais de Lacerda A. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease // Rev. Port. Cardiol. 2012. V. 31. № 11. P. 733–745. 40. Devaraj S., Xu D.Y., Jialai I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis // Circulation. 2003. V. 107. P. 398–404. 41. Torres J.L., Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events // Curr. Opin. Cardiol. 2003. V. 18. P. 471–478. 42. Venugopol S.K., Devaraj S., Yuhanna I. et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells // Circulation. 2002. V. 106. P. 1439–1441. 43. Verma S., Wang C.H., Li S.H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis // Circulation. 2002. V. 106. P. 913–919. 44. Fichtlscherer S., Rosenberger G., Walter D.H. et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease // Circulation. 2000. V. 102. P. 1000–1006. 45. Ridker P.M., Bassuk S.S., Toth P.P. C-reactive protein and risk of cardiovascular disease: evidence and clinical application // Curr. Atheroscler. Rep. 2003. V. 5. P. 341–349. 46. Ndumele C.E., Pradhan A.D., Ridker P.M. Interrelationships between inflammation, C-reactive protein and insulin resistance // J. Cardiometab. Syndr. 2006. V. 1. P. 190–196. 47. Danesh J., Wheeler J.G., Hirschfield G.M. et al. C-reactive protein and other circulating markers of inflammationin the prediction of coronary heart disease // N. Engl. J. Med. 2004. V. 350. P. 1387–1397. 48. Ridker P.M. Clinical usefulness of very high and very low levels of с –reactive protein across the full range of Framingham risk scores // Circulation. 2004. V. 109. P. 1955–1959. 49. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // N. Engl. J. Med. 2000. V. 342. P. 836–843. 50. Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men // N. Engl. J. Med. 1997. V. 336. P. 973–979. 51. Koenig W., Sund M., Fröhlich M. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the Monica Augsburg Cohort Study, 1984–1992 // Circulation. 1999. V. 99. P. 237–242. 52. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study // Am. J. Epidemiol. 1996. V. 144. P. 537–547. 53. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score // JAMA. 2007. V. 297. P. 611–619. 54. Ridker P.M., Paynter N.P., Rifai N. et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men // Circulation. 2008. V. 118. P. 2243–2251. 55. Ridker P.M. Clinical usefulness of very high and very low lewels of c-reactive protein across the full range of Framingham risk scores // Circulation. 2004. V. 109. P. 1955–1959. 56. Sattar N., Lowe G.D. High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundations? // Ann. Clin. Biochem. 2006. V. 43. P. 252–256. 57. Danesh J., Wheeler J.G., Hirschfield G.M. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease // N. Engl. J. Med. 2004. № 350. P. 1387–1397. 58. Lloyd-Jones D.M., Liu K., Tian L. Assessment of C-reactive protein in risk prediction for cardiovascular disease // Ann. Intern. Med. 2006. № 145. P. 35–42. 59. Wang T.J., Gona P., Larson M.G. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death // N. Engl. J. Med. 2006. № 355. P. 2631–2639. 60. Blankenberg S., Zeller T., Saarela O. et al.; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project // Circulation. 2010. № 121. P. 2388–2397. 61. Bo M., Corsinovi L., Brescianini A. et al. High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis // Angiology. 2009. V. 60. № 1. P. 12–20. 62. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC); Wensley F., Gao P., Burgess S., Kaptoge S. et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data // BMJ. 2011. V. 342. d548. 63. Iglseder B., Mackevics V., Stadlmayer A. et al. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study // Stroke. 2007. V. 36. № 12. P. 2577–2582. 64. Rothenbacher D., Brenner H., Marz W., Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers // Eur. Heart. J. 2005. V. 26. № 16. P. 1640–1646. 65. Otsuka F., Sugiyama S., Kojima S. et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease // J. Am. Coll. Cardiol. 2006. V. 48. № 6. P. 1155–1162. 66. Pischon T., Girman C.J., Hotamisligil G.S. et al. Plasma adiponectin levels and risk of myocardial infarction in men // JAMA. 2004. V. 291. № 14. P. 1730–1737. 67. Joosten M.M., Joshipura K.J., Pai J.K. et al. Total adiponectin and risk of symptomatic lower extremity peripheral artery disease in men // Arterioscler. Thromb. Vasc. Biol. 2013. V. 33. № 5. P. 1092–1097. 68. Komai H., Shibata R., Juri M. et al. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease // J. Vasc. Surg. 2009. V. 50. № 1. P. 95–99. 69. Laughlin G.A., Barrett-Connor E., May S., Langenberg C. // Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study // Am. J. Epidemiol. 2007. V. 165. № 2. P. 164–174. 70. Wannamethee S.G., Whincup P.H., Lennon L., Sattar N. // Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure // Arch. Intern. Med. 2007. V. 167. № 14. P. 1510–1517.    [ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]